NASDAQ:INFI

Infinity Pharmaceuticals (INFI) Stock Forecast, Price & News

$0.02

0.00 (0.00%)

(As of 09/20/2023 ET)

Compare

Today's Range: $0.02
▼
$0.02
50-Day Range: $0.02
▼
$0.24
52-Week Range: $0.02
▼
$1.30

Volume: 850,326 shs
Average Volume: 2.91 million shs
Market Capitalization: $2.07 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $1.50

Infinity Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 6,464.6% Upside
$1.50 Price Target
Short Interest: Healthy
2.43% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.50
Based on 7 Articles This Week
Insider Trading: Selling Shares
$28,714 Sold Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.77 out of 5 stars

3.0

Analyst's Opinion

Consensus Rating
Infinity Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $1.50, Infinity Pharmaceuticals has a forecasted upside of 6,464.6% from its current price of $0.02.
Amount of Analyst Coverage
Infinity Pharmaceuticals has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.43% of the outstanding shares of Infinity Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Infinity Pharmaceuticals has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Infinity Pharmaceuticals has recently increased by 12.18%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Infinity Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Infinity Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for INFI.

3.1

News and Social Media Coverage

News Sentiment
Infinity Pharmaceuticals has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Infinity Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
16 people have searched for INFI on MarketBeat in the last 30 days. This is an increase of 45% compared to the previous 30 days.
MarketBeat Follows
6 people have added Infinity Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Infinity Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,714.00 in company stock.
Percentage Held by Insiders
Only 9.81% of the stock of Infinity Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 22.14% of the stock of Infinity Pharmaceuticals is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Infinity Pharmaceuticals is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Infinity Pharmaceuticals is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Infinity Pharmaceuticals (NASDAQ:INFI) Stock

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.

INFI Price History

30 days | 90 days | 365 days | Advanced Chart

INFI Stock News Headlines

September 19, 2023 | americanbankingnews.com

StockNews.com Initiates Coverage on Infinity Pharmaceuticals (NASDAQ:INFI)

September 18, 2023 | stockhouse.com

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

September 21, 2023 | Wall Street Fundamentals (Ad)

How is This "Hidden Gem" Thriving in a Turbulent Market?

While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.

September 18, 2023 | americanbankingnews.com

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Sees Significant Increase in Short Interest

September 16, 2023 | prnewswire.com

INFINITY DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Infinity To Contact Him Directly To Discuss Their Options

September 16, 2023 | markets.businessinsider.com

ROSEN, A TOP RANKED LAW FIRM, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INFI

September 15, 2023 | stockhouse.com

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

September 14, 2023 | stockhouse.com

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

September 21, 2023 | Wall Street Fundamentals (Ad)

How is This "Hidden Gem" Thriving in a Turbulent Market?

September 13, 2023 | gurufocus.com

Director Adelene Perkins Sells 410,196 Shares of Infinity Pharmaceuticals Inc (INFI)

September 13, 2023 | stockhouse.com

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

September 13, 2023 | seekingalpha.com

Infinity Pharmaceuticals receives delisting determination letter from Nasdaq

September 12, 2023 | americanbankingnews.com

Infinity Pharmaceuticals (NASDAQ:INFI) Coverage Initiated by Analysts at StockNews.com

September 11, 2023 | stockhouse.com

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

September 6, 2023 | benzinga.com

INFI Stockholders Should Contact Robbins LLP for Information About the Class Action Involving Infinity Pharmaceuticals, Inc.

September 6, 2023 | stockhouse.com

Infinity Shareholder Notice

September 6, 2023 | finanznachrichten.de

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

September 5, 2023 | finance.yahoo.com

Three execs leave Infinity Pharmaceuticals after failed merger, layoffs

September 2, 2023 | stockhouse.com

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

August 28, 2023 | benzinga.com

INFI Stock News: Investors with Significant Losses in Infinity Pharmaceuticals, Inc. Should Contact Robbins LLP About Recovery

August 27, 2023 | prnewswire.com

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INFI

August 25, 2023 | markets.businessinsider.com

Infinity Shareholder Action Reminder

August 24, 2023 | businesswire.com

Infinity Pharmaceuticals, Inc. (INFI) Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Infinity Pharmaceuticals, Inc. Securities Class Action

August 23, 2023 | benzinga.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Infinity Pharmaceuticals, Inc. - INFI

August 21, 2023 | benzinga.com

Infinity Pharmaceuticals, Inc. (INFI) Shareholder Notice: Robbins LLP Reminds Investors of Class Action Filed Against Infinity Pharmaceuticals, Inc.

August 20, 2023 | prnewswire.com

ROSEN, A LEADING LAW FIRM, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INFI

August 19, 2023 | businesswire.com

INFINITY ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Infinity Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

See More Headlines

Receive INFI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Infinity Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

INFI Company Calendar

Last Earnings: 8/10/2023
Today: 9/21/2023
Next Earnings (Estimated): 11/13/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:INFI
CUSIP: 45665G30
CIK: 1113148
Web: www.infi.com
Phone: (617) 453-1000
Fax: 617-453-1001
Employees: 30
Year Founded: 2000

Price Target and Rating

Average Stock Price Forecast: $1.50
High Stock Price Forecast: $1.50
Low Stock Price Forecast: $1.50
Forecasted Upside/Downside: +6,464.6%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.46)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-44,370,000.00
Net Margins: -1,593.93%
Pretax Margin: -1,593.93%
Return on Equity: N/A
Return on Assets: -113.02%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.65
Quick Ratio: 1.65

Sales & Book Value

Annual Sales: $2.59 million
Price / Sales: 0.80
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.21) per share
Price / Book: -0.11

Miscellaneous

Outstanding Shares: 90,760,000
Free Float: 81,857,000
Market Cap: $2.07 million
Optionable: Optionable
Beta: 1.38

Social Links

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Ms. Adelene Q. Perkins (Age 63)
Chairman & CEO
Comp: $701.51k

Dr. Robert Ilaria Jr. (Age 62)
M.D., Chief Medical Officer
Comp: $653.8k

Dr. Lawrence E. Bloch J.D. (Age 57)
M.D., Treasurer
Comp: $513.61k

Ms. Melissa Hackel
VP of Fin.

Dr. Stephane Peluso Ph.D. (Age 52)
Chief Scientific Officer

Mr. Seth A. Tasker J.D. (Age 44)
Sr. VP, Chief Bus. Officer, Gen. Counsel & Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

INFI Stock - Frequently Asked Questions

Should I buy or sell Infinity Pharmaceuticals stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" INFI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INFI, but not buy additional shares or sell existing shares.
View INFI analyst ratings or view top-rated stocks.
What is Infinity Pharmaceuticals' stock price forecast for 2023?: 2 Wall Street analysts have issued twelve-month price targets for Infinity Pharmaceuticals' shares. Their INFI share price forecasts range from $1.50 to $1.50. On average, they anticipate the company's share price to reach $1.50 in the next year. This suggests a possible upside of 6,464.6% from the stock's current price.
View analysts price targets for INFI or view top-rated stocks among Wall Street analysts.
How have INFI shares performed in 2023?: Infinity Pharmaceuticals' stock was trading at $0.5550 on January 1st, 2023. Since then, INFI shares have decreased by 95.9% and is now trading at $0.0229.
View the best growth stocks for 2023 here.
Are investors shorting Infinity Pharmaceuticals?: Infinity Pharmaceuticals saw a increase in short interest in August. As of August 31st, there was short interest totaling 2,210,000 shares, an increase of 12.2% from the August 15th total of 1,970,000 shares. Based on an average trading volume of 3,370,000 shares, the short-interest ratio is presently 0.7 days.
View Infinity Pharmaceuticals' Short Interest.
When is Infinity Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our INFI earnings forecast.
How were Infinity Pharmaceuticals' earnings last quarter?: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) posted its earnings results on Thursday, August, 10th. The biotechnology company reported ($0.11) earnings per share for the quarter. The biotechnology company had revenue of $0.58 million for the quarter.

What is Adelene Q. Perkins' approval rating as Infinity Pharmaceuticals' CEO?: 10 employees have rated Infinity Pharmaceuticals Chief Executive Officer Adelene Q. Perkins on Glassdoor.com. Adelene Q. Perkins has an approval rating of 100% among the company's employees. This puts Adelene Q. Perkins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Infinity Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Continental Resources (CLR), Rex Energy (REXX), Aerie Pharmaceuticals (AERI), Gilead Sciences (GILD), OPKO Health (OPK), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Novavax (NVAX) and Celldex Therapeutics (CLDX).
What is Infinity Pharmaceuticals' stock symbol?: Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."
Who are Infinity Pharmaceuticals' major shareholders?: Infinity Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Carlson Capital L P (1.45%), Renaissance Technologies LLC (0.40%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Adelene Q Perkins and Bvf Partners L P/Il.
View institutional ownership trends.
How do I buy shares of Infinity Pharmaceuticals?: Shares of INFI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Infinity Pharmaceuticals' stock price today?: One share of INFI stock can currently be purchased for approximately $0.02.
How much money does Infinity Pharmaceuticals make?: Infinity Pharmaceuticals (NASDAQ:INFI) has a market capitalization of $2.07 million and generates $2.59 million in revenue each year. The biotechnology company earns $-44,370,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis.
How can I contact Infinity Pharmaceuticals?: Infinity Pharmaceuticals' mailing address is 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138. The official website for the company is www.infi.com. The biotechnology company can be reached via phone at (617) 453-1000, via email at irpr_info@infi.com, or via fax at 617-453-1001.

This page (NASDAQ:INFI) was last updated on 9/21/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial